Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

Summary

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

Timeline

Start

2019-05-08

Primary completion

2025-08-01

Completion

2026-06-30

Publications

• Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available.

Drugs

Indications